Atopic Dermatitis - Pipeline Insight, 2025

DelveInsight’s, “Atopic Dermatitis - Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Atopic Dermatitis: Understanding

Atopic Dermatitis: Overview

Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children. The primary symptom of AD is dry, itchy skin that often turns into a red rash. During a flare, AD becomes a red, itchy rash. Many different physical and internal factors can trigger an eczema flare-up. The resulting inflammation causes increased blood flow and the urge to itch. Eczema flares are part of the agonizing itch-scratch cycle that is hard to fight, leading to more inflammation and even skin infections. Skin can become dry and discolored, and repeated scratching may cause thickening and hardening of the skin (lichenification).

The pathophysiology of AD is complex and multifactorial, involving elements of barrier dysfunction, alterations in cell-mediated immune responses, IgE mediated hypersensitivity, and environmental factors. Loss of function mutations in filaggrin has been implicated in severe AD due to a potential increase in trans-epidermal water loss, pH alterations, and dehydration. Other genetic changes have also been identified which may alter the skin’s barrier function, resulting in an AD phenotype. The imbalance of Th2 to Th1 cytokines observed in AD can create alterations in the cell-mediated immune responses and promote IgE mediated hypersensitivity, both of which appear to play a role in the development of AD. Eczema can be characterized by spongiosis which allows inflammatory mediators to accumulate. Different dendritic cells subtypes, such as Langerhans cells, inflammatory dendritic epidermal cells, and plasmacytoid dendritic cells, play a major role in developing the condition.

Diagnosing atopic dermatitis typically involves providing the doctor with a comprehensive medical history, including details about family allergies, the presence of conditions like hay fever or asthma, sleep disturbances, potential triggers such as specific foods or irritants, previous treatments, and medication usage. The examination entails a thorough inspection of the skin and any present rash. Further diagnostic measures may include ordering laboratory tests, like blood tests to rule out alternative causes of the rash, or even a skin biopsy of the affected area. Given the complexity and variability of symptoms, multiple visits may be necessary for accurate diagnosis and to differentiate atopic dermatitis from other potential conditions.

Treating atopic dermatitis involves managing dry skin, reducing inflammation, controlling itching, promoting healing, preventing infections, and minimizing flare-ups. Your doctor tailors a plan based on factors like rash location, severity, individual triggers, and treatment response. This includes medications like moisturizers, corticosteroids, calcineurin inhibitors, and biologics.

""Atopic Dermatitis- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atopic Dermatitis pipeline landscape is provided which includes the disease overview and Atopic Dermatitis treatment guidelines. The assessment part of the report embraces, in depth Atopic Dermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Dermatitis.

Atopic Dermatitis Emerging Drugs Chapters

This segment of the Atopic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atopic Dermatitis Emerging Drugs

ICP-332: Innocare Pharma

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory bowel disease, etc., with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Atopic Dermatitis.

APG777: Apogee Therapeutics

APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of AD. In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. APG777 Phase 1 trial data out to 12 months demonstrated a half-life of 77 days, a consistent safety and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

Barzolvolimab: Celldex Therapeutics

Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

ATI-2138: Aclaris Therapeutics

ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3 for the potential treatment of T cell-mediated autoimmune diseases. The ITK/JAK3 compound interrupts T cell signaling through the combined inhibition of ITK/JAK3 pathways in lymphocytes. Aclaris is developing ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

STAR-0310: Astria Therapeutics

STAR-0310 is a monoclonal antibody designed as an OX40 antagonist, currently in preclinical development by Astria Therapeutics for the treatment of atopic dermatitis (AD) and potentially other immunologic conditions. Its mechanism of action involves inhibiting the OX40 receptor, which plays a critical role in T cell activation and survival, thereby modulating immune responses associated with AD. STAR-0310 is characterized by its high affinity and potency, coupled with a significantly reduced antibody-dependent cellular cytotoxicity (ADCC), which may lead to a more favorable safety profile and a broader therapeutic window compared to existing therapies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Atopic Dermatitis.

Further product details are provided in the report……..

Atopic Dermatitis: Therapeutic Assessment

This segment of the report provides insights about the different Atopic Dermatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atopic Dermatitis

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase III include, Innocare Pharma.

Phases

DelveInsight’s report covers around 120+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atopic Dermatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Atopic Dermatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Dermatitis drugs.

Atopic Dermatitis Report Insights

Atopic Dermatitis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Atopic Dermatitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Atopic Dermatitis drugs?

How many Atopic Dermatitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Dermatitis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Atopic Dermatitis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tradipitant

TDM 180935

ASN002

AX 158

Soquelitinib

YH 35324

BV-200

RLS 1496

ICP-332

APG777

Barzolvolimab

ATI-2138

STAR-0310

Key Products

Vanda Pharmaceuticals

TechnoDerma Medicines

Asana BioSciences

Artax Biopharma

Corvus Pharmaceuticals

Yuhan

BioVersys

Rubedo Life Sciences

Innocare Pharma

Apogee Therapeutics

Celldex Therapeutics

Aclaris Therapeutics

Astria Therapeutics

Please Note: It will take 3-4 business days to complete the report upon order confirmation.